XORTX Therapeutics Inc is a clinical-stage biotechnology company. The company focused on developing drug therapies for orphan diseases like polycystic kidney disease, and treatment of health consequences caused by chronic high serum uric acid which include cardiovascular disease and diabetes. XORTX Therapeutics Inc is a clinical-stage biotechnology company. The company focused on developing drug therapies for orphan diseases like polycystic kidney disease, and treatment of health consequences caused by chronic high serum uric acid which include cardiovascular disease and diabetes.
CALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -6.03448275862 | 1.16 | 1.25 | 1.06 | 18111 | 1.16030291 | CS |
4 | -0.16 | -12.8 | 1.25 | 1.4 | 1.06 | 16518 | 1.18656962 | CS |
12 | -0.58 | -34.7305389222 | 1.67 | 2.51 | 1.06 | 55352 | 1.74373494 | CS |
26 | -1.1 | -50.2283105023 | 2.19 | 2.9799 | 1.06 | 1455781 | 2.63932782 | CS |
52 | -1.39 | -56.0483870968 | 2.48 | 7 | 1.06 | 758788 | 2.66634131 | CS |
156 | -16.46 | -93.7891737892 | 17.55 | 22.32 | 1.06 | 549086 | 5.56107562 | CS |
260 | -118.07 | -99.0852635112 | 119.16 | 119.16 | 1.06 | 452625 | 9.47540912 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales